Feasibility and effectiveness of afatinib for poor performance status patients with EGFR-mutation-positive non-small-cell lung cancer: a retrospective cohort study

被引：0
|
作者：
Chiao-En Wu
Ching-Fu Chang
Chen-Yang Huang
Cheng-Ta Yang
Chih-Hsi Scott Kuo
Ping-Chih Hsu
John Wen-Cheng Chang
机构：
[1] Chang Gung University College of Medicine,Department of Internal Medicine, Division of Hematology
[2] Chang Gung University College of Medicine,Oncology, Chang Gung Memorial Hospital at Linkou
来源：
BMC Cancer | / 21卷
关键词：
Lung cancer; Afatinib; EGFR; TKI; Performance status;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] First-line osimertinib for poor performance status patients with EGFR mutation-positive non-small cell lung cancer: A prospective observational study
    Igawa, Satoshi
    Fukui, Tomoya
    Kasajima, Masashi
    Ono, Taihei
    Ozawa, Takahiro
    Kakegawa, Mikiko
    Kusuhara, Seiichiro
    Sato, Takashi
    Nakahara, Yoshiro
    Hisashi, Mitsufuji
    Sasaki, Jiichiro
    Naoki, Katsuhiko
    INVESTIGATIONAL NEW DRUGS, 2022, 40 (02) : 430 - 437
  • [22] Clinical Outcome and Toxicity Profiles of Patients with EGFR-mutation Positive Non-Small-Cell Lung Cancer
    Munawar, K.
    Sheikh, H.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S621 - S622
  • [23] A Multicenter Prospective Biomarker Study in Afatinib-Treated Patients with EGFR-Mutation Positive Non-Small Cell Lung Cancer
    Azuma, Koichi
    Iwama, Eiji
    Sakai, Kazuko
    Nozaki, Kaname
    Harada, Daijiro
    Hotta, Katsuyuki
    Ohyanagi, Fumiyoshi
    Kurata, Takayasu
    Akamatsu, Hiroaki
    Goto, Koichi
    Fukuhara, Tatsuro
    Nakanishi, Yoichi
    Okamoto, Isamu
    Nishio, Kazuto
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S299 - S299
  • [24] Role of osimertinib in the treatment of EGFR-mutation positive non-small-cell lung cancer
    Carlisle, Jennifer W.
    Ramalingam, Suresh S.
    FUTURE ONCOLOGY, 2019, 15 (08) : 805 - 816
  • [25] Irreversible tyrosine kinase inhibition of epidermal growth factor receptor with afatinib in EGFR activating mutation-positive advanced non-small-cell lung cancer
    Morin-Ben Abdallah, S.
    Hirsh, V.
    CURRENT ONCOLOGY, 2018, 25 : S9 - S17
  • [26] Sequential afatinib and osimertinib in patients withEGFRmutation-positive non-small-cell lung cancer: final analysis of the GioTag study
    Hochmair, Maximilian J.
    Morabito, Alessandro
    Hao, Desiree
    Yang, Cheng-Ta
    Soo, Ross A.
    Yang, James C-H
    Gucalp, Rasim
    Halmos, Balazs
    Marten, Angela
    Cufer, Tanja
    FUTURE ONCOLOGY, 2020, 16 (34) : 2799 - 2808
  • [27] The safety and efficacy of osimertinib for the treatment of EGFR T790M mutation positive non-small-cell lung cancer
    Gao, Xin
    Le, Xiuning
    Costa, Daniel B.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2016, 16 (04) : 383 - 390
  • [28] EGFR mutation status on brain metastases from non-small cell lung cancer
    Hsu, Fred
    De Caluwe, Alex
    Anderson, David
    Nichol, Alan
    Toriumi, Ted
    Ho, Cheryl
    LUNG CANCER, 2016, 96 : 101 - 107
  • [29] Phase II Study of Afatinib, an Irreversible ErbB Family Blocker, in EGFR FISH-Positive Non-Small-Cell Lung Cancer
    Cappuzzo, Federico
    Finocchiaro, Giovanna
    Grossi, Francesco
    Bidoli, Paolo
    Favaretto, Adolfo
    Marchetti, Antonio
    Valente, Maria Luisa
    Cseh, Agnieszka
    Clementi, Laura
    Massey, Dan
    Santoro, Armando
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (04) : 665 - 672
  • [30] Targeting EGFR mutation in non-small-cell lung cancer: challenges and future perspectives
    Haddad, Fady G.
    Kourie, Hampig R.
    Kattan, Joseph
    FUTURE ONCOLOGY, 2017, 13 (03) : 201 - 204
12345